KT-621 — Topline data
Late 2026
Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026Source filing
KYMR biotech catalysts & pipeline
KYMERA THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
KT-579 — Topline data
4Q26
KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 4Q26Source filing
KT-200 — IND submission
2027
Gilead Sciences exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader, generating a $45 million milestone, with IND planned in 2027Source filing
KT-621 — Topline data
late 2027
KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027Source filing